Alloimmune thrombocytopenia of the fetus and neonate is a condition characterized by a decrease in the level of platelets in the blood caused by the mother's immune response to fetal platelet antigens. This disease occurs when antibodies produced by the mother penetrate the placental barrier and are directed against fetal platelets, leading to their destruction. Alloimmune thrombocytopenia is one of the causes of hemorrhagic complications in newborns and can manifest itself with various clinical symptoms, including ecchymosis, petechial hemorrhages, and, in severe cases, intracerebral hematomas. Timely diagnosis and proper treatment of this condition are critical to reduce the risk of serious complications and improve the prognosis for the child.
History of the disease and interesting historical facts
The first mentions of thrombocytopenia date back to the early 20th century, but classification systems that would combine various causes of decreased platelet levels began to develop much later. In 1939, the relationship between thrombocytopenia and Rh incompatibility was described, which also became one of the foundations for understanding alloimmune thrombocytopenia. Studies of combinatorial antigen systems, such as the HLA system and other platelet antigens, began to be actively conducted starting in the 1970s, which contributed to a deeper understanding of the pathogenesis of this condition. In recent decades, the development of molecular genetics and immunofluorescence methods has significantly improved the possibilities of diagnosing and studying alloimmune thrombocytopenia, allowing the detection of specific antibodies and characterization of their impact on the health of newborns.
Epidemiology
Alloimmune thrombocytopenia is reported to occur in 1 in 1,000 to 2,000 live births, although this figure may vary by population and geographic region. It is most common in children whose mothers are Rh negative or lack certain platelet antigens. In 25-30% cases, there is a hereditary predisposition to the disease, which increases the risk of its development in subsequent generations. High incidence rates have also been reported among mothers who have had peripheral injections or transfusions, which is important to consider in clinical practice.
Genetic predisposition to this disease
Studies show that women with antibodies against platelet antigens of the HPA (Human Platelet Antigen) system may be predisposed to alloimmune thrombocytopenia. The most significant genes involved in the pathogenesis of this disease are the genes encoding platelet antigens HPA-1, HPA-3, and HPA-5. Mutations in these genes can lead to the formation of antibodies that subsequently activate the mechanism of platelet destruction in the fetus. In addition, certain haplotypes of genes associated with these antigens can increase the likelihood of developing alloimmune thrombocytopenia in populations with a high prevalence of similar genetic markers.
Risk factors for the development of this disease
The development of alloimmune thrombocytopenia can be influenced by many factors, including:
- Physical factors: previous pregnancies with thrombocytopenia, infectious diseases such as rubella or toxoplasmosis.
- Chemical factors: exposure of the mother's body to various toxic substances, including some medications and PVC.
- Genetic factors: Family history of the disease increases the risk of developing alloimmune thrombocytopenia in future generations.
- Perfusion and transfusion: Previous platelet transfusions may trigger antibody production in subsequent pregnancies.
These factors should be taken into account when planning pregnancy and managing women at risk.
Diagnosis of this disease
Diagnosis of alloimmune thrombocytopenia is based on a number of clinical studies and laboratory methods. The main symptoms are:
- Blue or red spots (petechiae) on the skin;
- Bleeding from the nose or gums;
- Severe bruising with minimal trauma;
- In rare cases: anemia and organ problems due to massive bleeding.
Laboratory tests include:
- Complete blood count to determine platelet levels;
- Specific tests for the presence of antibodies to platelet antigens (Coombs test);
- Mammographic history tests to rule out other causes of thrombocytopenia.
Radiologic examinations may be used to identify potential complications such as intracranial hematomas. The differential diagnosis includes ruling out other causes of thrombocytopenia such as the following:
- Thrombocytopenic purpura;
- Diseases of the blood system (leukemia, lymphoma);
- Genetically determined disorders of platelet function.
Treatment
Alloimmune thrombocytopenia requires an individual approach to each patient. General approaches to treatment include:
- Standby mode for mild cases with platelet monitoring;
- Pharmacological treatment including glucocorticoids (eg, prednisolone) to suppress immunosuppression and reduce the inflammatory response;
- Treatment with antiallergic drugs such as antihistamines;
- Platelet transfusion in severe cases when platelet levels are critically low;
- Plasmapheresis to remove antibodies from circulation.
Surgery may include interventions to stop massive bleeding, but this is rare. In addition to standard treatments, a new generation of immunosuppressants and monoclonal antibodies may hold promise.
List of medications used to treat this disease
The use of standard and new pharmacological agents includes:
- Prednisolone;
- Dextrans and rheopolyglucin;
- Antihistamines;
- Anti-CD20 monoclonal antibodies (rituximab);
- Human immunoglobulin for intravenous administration.
Disease monitoring
Management of a child with alloimmune thrombocytopenia requires regular monitoring of platelet counts and clinical status. The prognosis depends on the extent and severity of the disease. Many children, with adequate treatment, have a good outlook, although complications may develop, such as:
- Intracerebral hematomas;
- Organ dysfunction due to massive bleeding;
- Neurological complications in severe forms.
Recommendations for monitoring include regular clinical examinations, platelet testing, and adjustment of the treatment plan based on the patient's progress.
Age-related features of the disease
Alloimmune thrombocytopenia may present differently depending on the patient's age. Newborns often have more severe hemorrhagic complications, while older children may have a less severe condition.
- In newborns: high incidence of hemorrhagic symptoms; prevalence of intrauterine anemia.
- In older children: decreased frequency of hemorrhages, possible relapses due to infections and vaccinations.
- In adolescents and adults: the possibility of manifestation through newly appeared antibodies, which is possible due to slippage during transfusions.
Questions and Answers
- What are the main causes of alloimmune thrombocytopenia? The main causes include the presence of antibodies in the mother to the platelet antigens of the fetus, usually occurring when there is a Rh mismatch.
- How is this disease diagnosed? Diagnosis includes a complete blood count, specific antibody tests, and differential diagnosis considering other possible causes of thrombocytopenia.
- What is the treatment for alloimmune thrombocytopenia? Treatment includes the use of glucocorticoids, platelet transfusions, and plasmapheresis in severe cases.
- Does the disease affect the child's future health? With adequate treatment, most children with alloimmune thrombocytopenia have a good prognosis, but complications may occur.
- What are the recommendations for monitoring the condition? Regular testing of platelet levels, monitoring of symptoms and adjustment of the treatment process.
Advice from Dr. Oleg Korzhikov
It is important to remember that when planning a pregnancy, it is necessary to consider possible risks and factors that can lead to alloimmune thrombocytopenia. If you or your family have had cases of thrombocytopenia, it is worth discussing tests and possible precautions with a gynecologist or geneticist in advance. A monitoring program for women at risk will help to avoid serious complications and closely monitor the condition of the fetus. If there is a chance of developing the disease, the maximum amount of information and cooperation with medical personnel will significantly increase the likelihood of a successful outcome.
